Abstract Number: 2313 • ACR Convergence 2024
Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis
Background/Purpose: Studies have suggested a delay between symptom onset and diagnosis for Psoriatic Arthritis (PsA) and axial spondyloarthritis (axSpA). Factors that influence this delay have…Abstract Number: 1782 • ACR Convergence 2023
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…Abstract Number: 2137 • ACR Convergence 2023
Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) have an increasing array of treatment options available, and new blood-based diagnostic…Abstract Number: 2211 • ACR Convergence 2023
A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort
Background/Purpose: Treatment of axial spondyloarthritis (axSpA) has been shown to improve symptoms of the disease such as back pain (BP) and morning stiffness (MS). As…Abstract Number: 2252 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
Background/Purpose: PsA is a chronic disease affecting multiple domains; however, patients (pts) can experience loss of response with long-term therapy.1 Therefore, maintaining long-term treatment responses…Abstract Number: 0489 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients with psoriatic arthritis (PsA) in previous randomized clinical trials [1]. There is only limited…Abstract Number: 0527 • ACR Convergence 2023
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
Background/Purpose: Pain and fatigue have been identified by patients (pts) as key features of PsA, driving the impact on their health-related quality of life.1 Bimekizumab…Abstract Number: 0845 • ACR Convergence 2023
The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Background/Purpose: We have shown in the SPACE cohort that a diagnosis of early axial Spondyloarthritis (axSpA) can be reliably made in patients with chronic back…Abstract Number: 1397 • ACR Convergence 2023
Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…Abstract Number: 1783 • ACR Convergence 2023
Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis
Background/Purpose: Multiple lines of evidence indicate that ankylosing spondylitis (AS) is a lymphocyte-driven disease. However, which lymphocyte populations are critical in AS pathogenesis is not…Abstract Number: 2145 • ACR Convergence 2023
Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study
Background/Purpose: Based mainly on results from a randomized clinical trial (RCT) in rheumatoid arthritis (RA) patients (ORAL Surveillance), major regulatory agencies have concluded that JAK…Abstract Number: 2212 • ACR Convergence 2023
Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis
Background/Purpose: In axial spondyloarthritis (axSpA), assessment of disease activity and physical function in clinical studies relies on patient-reported outcomes (PRO) such as patient's global, BASDAI,…Abstract Number: 2437 • ACR Convergence 2023
Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy
Background/Purpose: In spondylarthropathy (SpA), such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS), arthritis is often associated with gut inflammation. After systemic β-1,3-glucan (curdlan) injection,…Abstract Number: 0492 • ACR Convergence 2023
Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?
Background/Purpose: It is known that patients diagnosed with axSpA do not subsequently meet the classification criteria. The Objectives are: To estimate the diagnostic prevalence of…Abstract Number: 0529 • ACR Convergence 2023
Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with axial spondyloarthritis (axSpA). IL-17A inhibition has demonstrated good efficacy on axSpA.…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 41
- Next Page »